Literature DB >> 10833615

Recent advances in the pre-mortem diagnosis of Creutzfeldt-Jakob disease.

S Collins1, A Boyd, A Fletcher, M F Gonzales, C A McLean, C L Masters.   

Abstract

Included in the spectrum of human transmissible spongiform encephalopathies are Creutzfeldt-Jakob disease (CJD) and the new variant form (vCJD), Gerstmann-Sträussler-Scheinker syndrome, fatal familial insomnia, kuru and various less distinct neuropsychiatric disorders. Progress in our understanding of this group of disorders continues at a prodigious rate, although important vexing practical issues persist. The definitive confirmation of symptomatic prion disease still requires pathological examination, most reliably performed post-mortem. However, paralleling the recent advances in the molecular biological understanding of normal prion protein (PrP(c)) function and the pathophysiology of prion diseases, there have been worthwhile developments in the pre-mortem diagnosis of CJD. Efforts to develop less invasive but very reliable ante-mortem diagnostic tests have received an additional impetus because of the potential epidemic of vCJD. Historically, the ancillary investigation of most merit has been the EEG, whereas the recent advances have encompassed a broader range of technologies, including both magnetic resonance and radioisotopic neuroimaging, and immunoassays for a range of non-specific marker proteins in both CSF, and less commonly, blood. However, given the recent refinement of sophisticated immunoassays, it is envisaged that the pathognomonic, protease-resistant, disease-associated isoforms of the prion protein (PrPres) may soon be directly detectable in the blood and tissues of patients manifesting or incubating a spongiform encephalopathy. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10833615     DOI: 10.1054/jocn.1999.0191

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  5 in total

1.  Progress in understanding Creutzfeldt-Jakob disease.

Authors:  Robin J Sellars; Donald A Collie; Robert J Will
Journal:  AJNR Am J Neuroradiol       Date:  2002-08       Impact factor: 3.825

2.  Classification of sporadic Creutzfeldt-Jakob disease based on clinical and neuropathological characteristics.

Authors:  José Cortiñas Abrahantes; Marc Aerts; Bart van Everbroeck; Claude Saegerman; Dirk Berkvens; Helena Geys; Koen Mintiens; Stefan Roels; Patrick Cras
Journal:  Eur J Epidemiol       Date:  2007-06-21       Impact factor: 8.082

3.  Creutzfeldt-Jakob Disease With Atypical Magnetic Resonance Imaging Features.

Authors:  Muhammad Sohaib Qamar; Amman Yousaf; Anum Nida
Journal:  Cureus       Date:  2020-11-02

4.  First participant diagnosed with Creutzfeldt-Jakob disease in the population-based Rotterdam Study was classified with mild cognitive impairment.

Authors:  Hata Karamujić-Čomić; Annemieke J M Rozemuller; M Arfan Ikram; Cornelia M van Duijn
Journal:  BMJ Case Rep       Date:  2021-03-29

Review 5.  Recombinant PrP and Its Contribution to Research on Transmissible Spongiform Encephalopathies.

Authors:  Jorge M Charco; Hasier Eraña; Vanessa Venegas; Sandra García-Martínez; Rafael López-Moreno; Ezequiel González-Miranda; Miguel Ángel Pérez-Castro; Joaquín Castilla
Journal:  Pathogens       Date:  2017-12-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.